Saluda Medical Revolutionizes Pain Management with EVA Launch
Saluda Medical Unleashes EVA™ Technology in U.S. Market
Saluda Medical, Inc., a trailblazer in innovative neuromodulation platforms, has proudly announced the full-scale launch of EVA, its cutting-edge sensing technology in the U.S. This advancement promises to redefine how patients with chronic neurological conditions experience pain relief. With FDA approval obtained by the end of last year, EVA is set to make a significant impact on patient care.
This groundbreaking device seamlessly integrates with the Evoke SmartLoop™ System, a comprehensive solution designed to enhance therapy for those suffering from various forms of chronic pain. EVA stands out by rigorously scanning and analyzing the spinal cord, thereby delivering personalized therapy that far exceeds traditional methods.
Transforming Patient Outcomes with Intelligent Therapy
The traditional approach to spinal cord stimulation often relied on manual programming, but with EVA, this process becomes streamlined and automated. Saluda Medical’s Chief Commercial Officer, Mike Mathias, expressed his enthusiasm, stating, "This full commercial launch signifies a monumental step forward in spinal cord stimulation (SCS) therapy, promoting more effective pain management capabilities for patients. Since its FDA approval, EVA has seen impressive use in over 3,000 patient visits through limited market release, proving its potential efficacy and versatility in real-world applications."
By utilizing patients' neural response biomarkers, known as the evoked compound action potential (ECAP), the Evoke SmartLoop System ensures optimal therapeutic levels tailored to individual needs. This unique feature aims to enhance patient experiences and outcomes dramatically.
Upcoming Clinical Data Presentation
Anticipation builds as Saluda Medical prepares to present new clinical findings regarding EVA at the upcoming American Society of Pain and Neuroscience (ASPN) 2025 Annual Conference. This conference will be a platform for sharing significant research, including 11 abstracts and one oral presentation, showcasing Saluda's extensive clinical evidence, which now includes 37 published studies.
Dr. Jason Pope, Founder and CEO of Evolve Restorative Center, highlighted, "The combination of the Evoke SmartLoop System and EVA delivers objective dosing, paving the path for predictable, enduring outcomes in SCS. The research shared at ASPN will further emphasize the substantial clinical benefits, particularly in maximizing the trial phase's diagnostic value and ensuring sustained therapy responses over time, all without sacrificing efficacy."
About Saluda Medical and Its Innovations
As a commercial-stage medical device company, Saluda Medical's focus lies in creating solutions for chronic neurological conditions through their pioneering neuromodulation platform. Their closed-loop therapy system not only senses but also measures neural responses, allowing for real-time adjustments tailored to each patient's unique physiological feedback.
The company’s flagship product, the Evoke® System, is designed to assist in managing complex chronic pains, including those associated with failed back surgery syndrome and neuropathic conditions, effectively reducing the burden on both patients and clinicians alike. The groundbreaking EVOKE study was a landmark, being the only prospective, multi-center study in SCS to deliver significant results published across prominent medical journals, including results from The Lancet Neurology and JAMA Neurology.
Contact Information for Investors
For those interested in learning more about Saluda Medical’s innovations or for investor inquiries, reach out to Brian Johnston or Sam Bentzinger directly. Engaging with their team provides an opportunity for anyone to discover how Saluda is reshaping care for patients facing chronic pain challenges.
Frequently Asked Questions
What is the EVA™ technology?
The EVA™ technology is a next-generation sensing platform designed to deliver personalized spinal cord stimulation therapy based on real-time neural responses.
How does the Evoke SmartLoop™ System work?
The Evoke SmartLoop™ System continuously monitors a patient's neural responses and adjusts stimulation to optimize therapy outcomes.
What benefits does EVA™ offer to patients?
EVA™ provides objective dosing for more effective, predictable, and longer-lasting pain relief, enhancing the overall patient experience during therapy.
What kind of clinical data will be presented at ASPN 2025?
New clinical findings showcasing the effectiveness and benefits of EVA will be presented through 11 abstracts and one oral presentation at the ASPN conference.
How can one learn more about Saluda Medical’s products?
Detailed information about their offerings and safety information is accessible through their official website contact points.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
